S. Hart

发表

Arthritis and C-fms for the Treatment of Rheumatoid Sb1578, a Novel Inhibitor of Jak2, Flt3

J. Wood, B. Madan, K. Goh, 2022 .

SB1578, a Novel Inhibitor of JAK2, FLT3, and c-Fms for the Treatment of Rheumatoid Arthritis

J. Wood, A. William, B. Dymock, 2012, The Journal of Immunology.

SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies

A. Poulsen, A. William, B. Dymock, 2011, Leukemia.

TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties

J. Wood, A. William, B. Dymock, 2012, Leukemia.

Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes.

J. Shah, J. Wood, P. Mclaughlin, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EGFR signaling leads to downregulation of PTP-LAR via TACE-mediated proteolytic processing.

A. Ullrich, S. Hart, J. Ruhe, 2006, Cellular signalling.

VS-5584 mediates potent anti-myeloma activity via the upregulation of a class II tumor suppressor gene, RARRES3 and the activation of Bim

W. Chng, S. Hart, N. Mustafa, 2017, Oncotarget.

Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide.

S. Hart, W. Sun, D. Hwang, 1992, The Journal of biological chemistry.

Scalable spheroid model of human hepatocytes for hepatitis C infection and replication.

Hanry Yu, S. Sankuratri, S. Hart, 2014, Molecular pharmaceutics.

Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) for the treatment of rheumatoid arthr

J. Wood, A. Poulsen, A. William, 2012, Journal of medicinal chemistry.

Dissecting the epidermal growth factor receptor signal transactivation pathway.

A. Ullrich, S. Hart, O. Fischer, 2006, Methods in molecular biology.

Revealed by Novel TYK2-Selective Inhibitors Activity in Human Cytokine Responses A Restricted Role for TYK2 Catalytic

Adam R. Johnson, N. Lewin-Koh, Lawren C. Wu, 2013 .

Molecular Cancer Therapeutics SB 939 , a Novel Potent and Orally Active Histone Deacetylase Inhibitor with High Tumor Exposure and Efficacy in Mouse Models of Colorectal Cancer

Z. Bonday, J. Wood, Haishan Wang, 2010 .

Advances in Brief Cannabinoids Induce Cancer Cell Proliferation via Tumor Necrosis Factor-Converting Enzyme ( TACE / ADAM 17 )-Mediated Transactivation of the Epidermal Growth Factor Receptor

A. Ullrich, S. Hart, O. Fischer, 2004 .

Reduction of HBV replication prolongs the early immunological response to IFNα therapy.

H. Bitter, A. Bertoletti, M. Hibberd, 2014, Journal of hepatology.

TACE cleavage of proamphiregulin regulates GPCR‐induced proliferation and motility of cancer cells

Stefan Hart, A. Ullrich, S. Hart, 2003, The EMBO journal.

Cannabinoids Induce Cancer Cell Proliferation via Tumor Necrosis Factor α-Converting Enzyme (TACE/ADAM17)-Mediated Transactivation of the Epidermal Growth Factor Receptor

A. Ullrich, S. Hart, O. Fischer, 2004, Cancer Research.

EGFR signal transactivation in cancer cells.

A. Ullrich, S. Hart, A Ullrich, 2003, Biochemical Society transactions.

The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells

A. Ullrich, H. Ho, S. Hart, 2010, Oncogene.

The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML

J. Wood, K. Goh, K. Ethirajulu, 2012, Blood Cancer Journal.

Mammary Gland Remodeling Depends on gp130 Signaling through Stat3 and MAPK*

A. Ullrich, L. Hennighausen, C. Stewart, 2004, Journal of Biological Chemistry.

The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification.

A. Ullrich, S. Hart, A Ullrich, 2001, Endocrine-related cancer.

GPCR-induced migration of breast carcinoma cells depends on both EGFR signal transactivation and EGFR-independent pathways

A. Ullrich, L. Hennighausen, S. Hart, 2005, Biological chemistry.

Oxidative and Osmotic Stress Signaling in Tumor Cells Is Mediated by ADAM Proteases and Heparin-Binding Epidermal Growth Factor

A. Ullrich, S. Hart, N. Prenzel, 2004, Molecular and Cellular Biology.

Growth Factor Proteases and Heparin-Binding Epidermal Tumor Cells Is Mediated by ADAM Oxidative and Osmotic Stress Signaling in

A. Ullrich, S. Hart, N. Prenzel, 2004 .

Epidermal Growth Factor Receptor Signal Trans-Activation

A. Ullrich, S. Hart, A. Roidl, 2003 .

Effect of Ang-2-VEGF-A Bispecific Antibody in Renal Cell Carcinoma

Markus Thomas, Dachuan Huang, C. Ong, 2015, Cancer investigation.

SB939, a Novel Potent and Orally Active Histone Deacetylase Inhibitor with High Tumor Exposure and Efficacy in Mouse Models of Colorectal Cancer

Z. Bonday, J. Wood, Haishan Wang, 2010, Molecular Cancer Therapeutics.

Alterations in Ca2+ transport ATPase and P-glycoprotein expression can mediate resistance to thapsigargin.

J. Gutheil, S. Hart, C. Belani, 1994, The Journal of biological chemistry.

Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lympho

Anders Poulsen, Stéphanie Blanchard, Harish Nagaraj, 2011, Journal of medicinal chemistry.

Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia

J. Wood, J. Zhou, B. Madan, 2011, Blood cancer journal.

Beyond Herceptin and Gleevec.

A. Ullrich, S. Hart, O. Fischer, 2003, Current opinion in chemical biology.

Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines.

S. Brenner, B. Venkatesh, A. Ullrich, 2007, Cancer research.

Chemical Therapeutics VS-5584 , a Novel and Highly Selective PI 3 K / mTOR Kinase Inhibitor for the Treatment of Cancer

U. McDermott, M. Garnett, C. Benes, 2013 .

VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer

U. McDermott, M. Garnett, C. Benes, 2012, Molecular Cancer Therapeutics.

Structure and Ligand-Based Design of mTOR and PI3-Kinase Inhibitors Leading to the Clinical Candidates VS-5584 (SB2343) and SB2602

Anders Poulsen, Stéphanie Blanchard, Angeline Lee, 2014, J. Chem. Inf. Model..

Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.

A. Ullrich, M. Aung, S. Lim, 2009, Journal of hepatology.

416 The oral HDAC inhibitor SB939 shows activity in in vitro and in vivo models of acute myeloid leukemia

J. Wood, Haishan Wang, K. Goh, 2010 .

A. Ullrich, M. Aung, S. Lim, 2009, Journal of hepatology.

Characterisation of the molecular mechanisms of EGFR signal transactivation in human cancer

J. Würzburg, S. Hart, 2004 .

nonaene ( SB 1578 ) , a Potent Inhibitor of Janus Kinase 2 / Fms-LikeTyrosine Kinase-3 ( JAK 2 / FLT 3 ) for the Treatment of Rheumatoid Arthritis

Anders Poulsen, Harish Nagaraj, Evelyn Tan, 2012 .

SB1578, a Novel Inhibitor of JAK2, FLT3, and c-Fms for the Treatment of Rheumatoid Arthritis

J. Wood, A. William, B. Dymock, 2012, The Journal of Immunology.

Scalable spheroid model of human hepatocytes for hepatitis C infection and replication.

Hanry Yu, S. Sankuratri, S. Hart, 2014, Molecular pharmaceutics.

SB939, a Novel Potent and Orally Active Histone Deacetylase Inhibitor with High Tumor Exposure and Efficacy in Mouse Models of Colorectal Cancer

J. Wood, Haishan Wang, S. Pettersson, 2010, Molecular Cancer Therapeutics.

A. Ullrich, M. Aung, S. Lim, 2009, Journal of hepatology.

VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer

U. McDermott, M. Garnett, C. Benes, 2012, Molecular Cancer Therapeutics.

This information is current as Arthritis and c-Fms for the Treatment of Rheumatoid SB 1578 , a Novel Inhibitor of JAK 2 , FLT 3 , Dymock and

B. Madan, K. Goh, K. Ethirajulu, 2012 .